{"doc_id": "si-2023-0697-reg-1", "parent_doc_id": "si-2023-0697", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 697 of 2023", "title": "2006)) of the Irish Medicines Board Act 1995 (No. 29 of 1995), hereby make", "year": 2023, "heading": "1. These Regulations may be cited as the Health Products Regulatory", "text_raw": "1. These Regulations may be cited as the Health Products Regulatory \n\nAuthority (Fees) Regulations 2023.", "text_norm": "1 regulation may cited health product regulatory authority (fees) regulation 2023", "start_char": 596, "end_char": 703, "source_path": "downloads\\2023\\2023_0697.pdf", "extraction_method": "pdfminer", "checksum": "sha256:2f26e4f67c6e8c1b721b56ab04ed177d6e8a27016037c5889b972b69326b3951", "cross_refs": []}
{"doc_id": "si-2023-0697-reg-2", "parent_doc_id": "si-2023-0697", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 697 of 2023", "title": "2006)) of the Irish Medicines Board Act 1995 (No. 29 of 1995), hereby make", "year": 2023, "heading": "In these Regulations—", "text_raw": "2. \n\nIn these Regulations— \n\n“Act of 1995” means the Irish Medicines Board Act 1995 (No. 29 of 1995); \n\n“Act of 2006” means the Irish Medicines Board (Miscellaneous Provisions) \nAct 2006 (No. 3 of 2006); \n\n“active substances register” has the meaning assigned to it by Regulation 3(1) \n(inserted by Regulation 3(a) of \nthe Medicinal Products (Control of \nManufacture) (Amendment) Regulations 2013 (S.I. No. 163 of 2013)) of the \nMedicinal Products (Control of Manufacture) Regulations 2007 (S.I. No. 539 \nof 2007); \n\n“authorised representative” means a person established within the European \nEconomic Area who, explicitly designated by the manufacturer, acts for the \nmanufacturer and may be addressed by authorities and bodies in the European \nEconomic Area instead of the manufacturer with respect to the European \nCommunities (Medical Devices) Regulations 1994 (S.I. No. 252 of 1994), the \nEuropean Communities (Active Implantable Medical Devices) Regulations \n1994 (S.I. No. 253 of 2004), or the European Communities (In Vitro \nDiagnostic Medical Devices) Regulations 2001 (S.I. No. 304 of 2001), or has \nthe meaning assigned to it by— \n\n(a) Article 2(32) of the Medical Devices Regulation, or \n\n(b) Article 2(25) of the IVD Medical Devices Regulation, as \n\napplicable; \n\n“Authority” means the Health Products Regulatory Authority; \n\n“breeder authorisation” has the meaning assigned to it by Regulation 3(1) of \nthe Protection of Animals Regulations; \n\n“broker” means a person carrying out the brokering of medicinal products, as \ndefined in Regulation 4(1) (as amended by Regulation 3(a) \n\nof the Medicinal Products (Control of Wholesale Distribution) (Amendment) \nRegulations 2013 (S.I. No. 164 of 2013)) of the Control of Wholesale \nDistribution Regulations; \n\nNotice of the making of this Statutory Instrument was published in \n\"Iris Oifigiúil\" of 26th December, 2023. \n\n \n \n \n \n \n\f[697] 3 \n\n“brokers register” has the meaning assigned to it by Regulation 4(1) (as \namended by Regulation 3(a) of the Medicinal Products (Control of Wholesale \nDistribution) (Amendment) Regulations 2013) of the Control of Wholesale \nDistribution Regulations; \n\n“certificate of free sale” means – \n\n(a) \n\n(b) \n\n(c) \n\na certificate of free sale issued under section 4(1)(k)(ii) (as \namended by section 11(a)(iii) of the Act of 2006) of the Act of \n1995, \n\na certificate of free sale issued under Article 60 of the Medical \nDevices Regulation, or \n\na certificate of free sale issued under Article 55 of the IVD \nMedical Devices Regulation; \n\n“certificate of registration” has the meaning assigned to it by Regulation 3(1) \nof the Control of Placing on the Market Regulations; \n\n“certificate of traditional-use registration” has the meaning assigned to it by \nRegulation 3(1) of the Control of Placing on the Market Regulations; \n\n“certification of documents” means the certification, under section 4(1)(k)(ii) \n(as amended by section 11(a)(iii) of the Act of 2006) of the Act of 1995, of \ndocuments not being certificates of free sale or export certificates; \n\n“complex dossier” refers to an application accompanied by a full dossier in \naccordance with Directive 2001/83/EC; \n\n“Control of Placing on the Market Regulations” means the Medicinal Products \n(Control of Placing on the Market) Regulations 2007 (S.I. No. 540 of 2007); \n\n“Control of Wholesale Distribution Regulations” means the Medicinal \nProducts (Control of Wholesale Distribution) Regulations 2007 (S.I. No. 538 \nof 2007); \n\n“decentralised procedure” means the decentralised procedure for human \nmedicinal products provided for in Directive 2001/83/EC; \n\n“device” means – \n\n(a) \n\na medical device, \n\n(b) \n\nan accessory for a medical device, \n\n(c) \n\na product listed in Annex XVI to the Medical Devices \nRegulation, provided that the Medical Devices Regulation \napplies to such product pursuant to Article 1(2) thereof, \n\n(d) \n\nan in vitro diagnostic medical device, or \n\n(e) \n\nan accessory for an in vitro diagnostic medical device, \n\nbut does not include- \n\n(i) \n\na product or other substance excluded by Article 1(6)(b) to \n(i) of the Medical Devices Regulation, \n\n \n\f4 [697] \n\n(ii) \n\na product or other substance excluded from the scope of \nthe IVD Medical Devices Regulation by Article 1(3) \nthereof, \n\n(iii) a device referred to in the second subparagraph of Article \n1(8), (9) or (10) of the Medical Devices Regulation, or \n\n(iv) an in-house device; \n\n“Directive 2001/83/EC” means Directive 2001/83/EC of the European \nParliament and of the Council of 6 November 20011; \n\n“distributor”, in the context of devices, means any natural or legal person in the \nsupply chain, other than the manufacturer or the importer, that makes a device \navailable on the market, up until the point of putting into service; \n\n“export certificate” means an export certificate issued under section 4(1)(k)(ii) \n(as amended by section 11(a)(iii) of the Act of 2006) of the Act of 1995; \n\n“European Union Reference Laboratory” means a laboratory designated under \nArticle 100 of the IVD Medical Devices Regulation. \n\n“follow-up inspections” means inspections other than routine inspections; \n\n“homeopathic medicinal product” has the meaning assigned to it by Regulation \n3(1) of the Control of Placing on the Market Regulations; \n\n“importer”, in the context of devices, means any natural or legal person \nestablished within the European Economic Area that places a device from a \nthird country on the market in the European Economic Area; \n\n“individual authorisation” means an authorisation granted to an individual \nunder Part 8 of the Protection of Animals Regulations; \n\n“investigational medicinal product” has the meaning assigned to it by \nRegulation 3(1) (as amended by Regulation 4(g) of the Medicinal Products \n(Control of Manufacture) (Amendment) Regulations 2022 (S.I. No. 43 of \n2022)) of the Medicinal Products (Control of Manufacture) Regulations 2007; \n\n“in vitro diagnostic medical device” has the meaning assigned to it by— \n\n(a) Article 2(2) of the IVD Medical Devices Regulation, or \n\n(b) Regulation 2(1) of the European Communities (In Vitro \nDiagnostic Medical Devices) Regulations 2001 (S.I. No. 304 of \n2001), \n\nas applicable; \n\n“IVD Medical Devices Regulation” means Regulation (EU) 2017/746 of the \nEuropean Parliament and of the Council of 5 April 20172; \n\n“listed organisation” has the meaning assigned to it by Regulation 4(1) (as \namended by Regulation 3 of the Medicinal Products (Prescription and Control \nof Supply) (Amendment) (No. 4) Regulations 2021 (S.I. No. 81 of 2021)) of \nthe Medicinal Products (Prescription and Control of Supply) Regulations 2003 \n(S.I. No. 540 of 2003); \n\n1 OJ No. L 311, 28.11.2001, p. 67. \n2 OJ No. L 117, 5.5.2017, p. 176. \n\n \n \n\f[697] 5 \n\n“manufacturer”, in the context of devices, means a person who assembles, \npackages, processes, fully refurbishes or labels one or more ready-made \nproducts or assigns to them their intended purpose as a device with a view to \ntheir being placed on the market under his or her own name, but not including a \nperson which assembles or adapts devices already on the market to their \nintended purpose for an individual patient, or has the meaning assigned to it \nby— \n\n(a) Regulation \n\n2(1) of the European Communities (Medical \n\nDevices) Regulations 1994, \n\n(b) Regulation 2(1) of \n\nthe European Communities \n\n(Active \n\nImplantable Medical Devices) Regulations 1994, \n\n(c) \n\nby Regulation 2(1) of the European Communities (In vitro \nDiagnostic Medical Devices) Regulations 2001, \n\n(d) Article 2(30) of the Medical Devices Regulation, or \n\n(e) Article 2(23) of the IVD Medical Devices Regulation, as \n\napplicable; \n\n“manufacturer’s authorisation” has the meaning assigned to it by Regulation \n3(1) of the Medicinal Products (Control of Manufacture) Regulations 2007; \n\n“manufacturing facility”, in the context of devices, means a place where an \nentity, which does not place devices on the market under its own name or \nunder its own trademark— \n\n(a) manufactures a device, \n\n(b) manufactures one or more critical components of a device to a \n\nset of specifications, \n\n(c) \n\ncarries out packaging activities in relation to a device, or \n\n(d) \n\ncarries out labelling activities in relation to a device; \n\n“marketing authorisation” means a marketing authorisation granted pursuant to \nthe Control of Placing on the Market Regulations; \n\n“medical device” has the meaning— \n\n(a) \n\n(b) \n\n(c) \n\n(d) \n\nassigned to it by Article 2(1) of the Medical Devices Regulation, \n\nassigned to it by Article 2(2) of the IVD Medical Devices \nRegulation, \n\nassigned to the term “device” by Regulation 2(1) of the \nEuropean Communities (Medical Devices) Regulations 1994, or \n\nassigned to the term “device” by Regulation 2(1) of the \nEuropean Communities (Active Implantable Medical Devices) \nRegulations 1994, \n\nas applicable; \n\n“Medical Devices Regulation” means Regulation (EU) 2017/745 of the \nEuropean Parliament and of the Council of 5 April 20173; \n\n3 OJ No. L 117, 5.5.2017, p. 1. \n\n \n \n\f6 [697] \n\n“mutual recognition procedure” means the mutual recognition procedure for \nhuman medicinal products provided for in Directive 2001/83/EC; \n\n“national rules scheme” means the national rules governing the granting of \nmarketing authorisation in respect of homeopathic medicinal products, as \nprovided in Regulation 11 of the Control of Placing on the Market Regulations; \n\n“notified body” means, in relation to any task, a body designated and notified \nin respect of that task in accordance with the European Communities (Medical \nDevices) Regulations 1994, the European Communities (Active Implantable \nMedical Devices) Regulations 1994, or the European Communities (In Vitro \nDiagnostic Medical Devices) Regulations 2001, or has the meaning assigned to \nit by— \n\n(a) Article 2(42) of the Medical Devices Regulation, or \n\n(b) Article 2(34) of the IVD Medical Devices Regulation, as \n\napplicable; \n\n“organ establishment authorisation” means an authorisation granted pursuant to \nRegulation 6 of the European Union (Quality and Safety of Human Organs \nIntended for Transplantation) Regulations 2012 (S.I. No. 325 of 2012); \n\n“parallel import licence” has the meaning assigned to it by Regulation 3(1) of \nthe Control of Placing on the Market Regulations; \n\n“project” and “project authorisation” have the meanings assigned to them by \nRegulation 3(1) of the Protection of Animals Regulations; \n\n“Protection of Animals Regulations” means the European Union (Protection of \nAnimals used for Scientific Purposes) Regulations 2012 (S.I. No. 543 of 2012); \n\n“reduced dossier – complex” refers to an application for a generic medicinal \nproduct accompanied by a reduced dossier but containing additional data in \ncircumstances required by Directive 2001/83/EC; \n\n“reduced dossier – standard” refers to an application for a generic medicinal \nproduct accompanied by a reduced dossier in accordance with Directive \n2001/83/EC; \n\n“service item” means an application for a medicinal product designated by the \nAuthority as qualifying for a reduced application fee on the basis that the \nproduct has limited but important uses for which no alternative authorised \nproduct exists; \n\n“subsequent extension applications” means applications \nto \nadditional pharmaceutical forms and strengths of a medicinal product, made \nsubsequent to the first application in relation to that product; \n\nin relation \n\n“supplier authorisation” has the meaning assigned to it by Regulation 3(1) of \nthe Protection of Animals Regulations; \n\n“system or procedure pack producer” means a natural or legal person referred \nto in— \n\n(a) Article 22(1), (2) or (3) of the Medical Devices Regulation, or \n\n \n\f[697] 7 \n\n(b) Article 12 of Council Directive 93/42/EEC of 14th June 19934, \n\nas applicable; \n\n“switching applications” means applications for a change in the classification \nof medicinal products under Title VI of Directive 2001/83/EC; \n\n“traditional herbal medicinal product” has the meaning assigned to it by \nRegulation 3(1) of the Control of Placing on the Market Regulations; \n\n“type IA variation”, “type IB variation” and “type II standard variation” refer \nto classifications by the Authority in accordance with Commission Regulation \n(EC) No. 1234/2008 of 24 November 20085; \n\n“user authorisation” has the meaning assigned to it by Regulation 3(1) of the \nProtection of Animals Regulations; \n\n“wholesaler’s authorisation” has the meaning assigned to it by Regulation 4(1) \nof the Medicinal Products (Control of Wholesale Distribution) Regulations", "text_norm": "2 regulations-- act 1995 mean irish medicine board act 1995 (no 29 1995) act 2006 mean irish medicine board (miscellaneous provisions) act 2006 (no 3 2006) active substance register meaning assigned regulation 3(1) (inserted regulation 3(a) medicinal product (control manufacture) (amendment) regulation 2013 (s.i no 163 2013)) medicinal product (control manufacture) regulation 2007 (s.i no 539 2007) authorised representative mean person established within european economic area explicitly designated manufacturer act manufacturer may addressed authority body european economic area instead manufacturer respect european community (medical devices) regulation 1994 (s.i no 252 1994) european community (active implantable medical devices) regulation 1994 (s.i no 253 2004) european community (in vitro diagnostic medical devices) regulation 2001 (s.i no 304 2001) meaning assigned by-- (a) article 2(32) medical device regulation (b) article 2(25) ivd medical device regulation applicable authority mean health product regulatory authority breeder authorisation meaning assigned regulation 3(1) protection animal regulation broker mean person carrying brokering medicinal product defined regulation 4(1) (as amended regulation 3(a) medicinal product (control wholesale distribution) (amendment) regulation 2013 (s.i no 164 2013)) control wholesale distribution regulation notice making statutory instrument published iris oifigiuil 26th december 2023 697 3 broker register meaning assigned regulation 4(1) (as amended regulation 3(a) medicinal product (control wholesale distribution) (amendment) regulation 2013) control wholesale distribution regulation certificate free sale mean - (a) (b) (c) certificate free sale issued section 4(1)(k)(ii) (as amended section 11(a)(iii) act 2006) act 1995 certificate free sale issued article 60 medical device regulation certificate free sale issued article 55 ivd medical device regulation certificate registration meaning assigned regulation 3(1) control placing market regulation certificate traditional-use registration meaning assigned regulation 3(1) control placing market regulation certification document mean certification section 4(1)(k)(ii) (as amended section 11(a)(iii) act 2006) act 1995 document certificate free sale export certificate complex dossier refers application accompanied full dossier accordance directive 2001 83 ec control placing market regulation mean medicinal product (control placing market) regulation 2007 (s.i no 540 2007) control wholesale distribution regulation mean medicinal product (control wholesale distribution) regulation 2007 (s.i no 538 2007) decentralised procedure mean decentralised procedure human medicinal product provided directive 2001 83 ec device mean - (a) medical device (b) accessory medical device (c) product listed annex xvi medical device regulation provided medical device regulation applies product pursuant article 1(2) thereof (d) vitro diagnostic medical device (e) accessory vitro diagnostic medical device include- (i) product substance excluded article 1(6)(b) (i) medical device regulation 4 697 (ii) product substance excluded scope ivd medical device regulation article 1(3) thereof (iii) device referred second subparagraph article 1(8) (9) (10) medical device regulation (iv) in-house device directive 2001 83 ec mean directive 2001 83 ec european parliament council 6 november 20011 distributor context device mean natural legal person supply chain manufacturer importer make device available market point putting service export certificate mean export certificate issued section 4(1)(k)(ii) (as amended section 11(a)(iii) act 2006) act 1995 european union reference laboratory mean laboratory designated article 100 ivd medical device regulation follow-up inspection mean inspection routine inspection homeopathic medicinal product meaning assigned regulation 3(1) control placing market regulation importer context device mean natural legal person established within european economic area place device third country market european economic area individual authorisation mean authorisation granted individual part 8 protection animal regulation investigational medicinal product meaning assigned regulation 3(1) (as amended regulation 4(g) medicinal product (control manufacture) (amendment) regulation 2022 (s.i no 43 2022)) medicinal product (control manufacture) regulation 2007 vitro diagnostic medical device meaning assigned by-- (a) article 2(2) ivd medical device regulation (b) regulation 2(1) european community (in vitro diagnostic medical devices) regulation 2001 (s.i no 304 2001) applicable ivd medical device regulation mean regulation (eu) 2017 746 european parliament council 5 april 20172 listed organisation meaning assigned regulation 4(1) (as amended regulation 3 medicinal product (prescription control supply) (amendment) (no 4) regulation 2021 (s.i no 81 2021)) medicinal product (prescription control supply) regulation 2003 (s.i no 540 2003) 1 oj no l 311 28.11.2001 p 67 2 oj no l 117 5.5.2017 p 176 697 5 manufacturer context device mean person assembles package process fully refurbishes label one ready-made product assigns intended purpose device view placed market name including person assembles adapts device already market intended purpose individual patient meaning assigned by-- (a) regulation 2(1) european community (medical devices) regulation 1994 (b) regulation 2(1) european community (active implantable medical devices) regulation 1994 (c) regulation 2(1) european community (in vitro diagnostic medical devices) regulation 2001 (d) article 2(30) medical device regulation (e) article 2(23) ivd medical device regulation applicable manufacturer authorisation meaning assigned regulation 3(1) medicinal product (control manufacture) regulation 2007 manufacturing facility context device mean place entity place device market name trademark-- (a) manufacture device (b) manufacture one critical component device set specification (c) carry packaging activity relation device (d) carry labelling activity relation device marketing authorisation mean marketing authorisation granted pursuant control placing market regulation medical device meaning-- (a) (b) (c) (d) assigned article 2(1) medical device regulation assigned article 2(2) ivd medical device regulation assigned term device regulation 2(1) european community (medical devices) regulation 1994 assigned term device regulation 2(1) european community (active implantable medical devices) regulation 1994 applicable medical device regulation mean regulation (eu) 2017 745 european parliament council 5 april 20173 3 oj no l 117 5.5.2017 p 1 6 697 mutual recognition procedure mean mutual recognition procedure human medicinal product provided directive 2001 83 ec national rule scheme mean national rule governing granting marketing authorisation respect homeopathic medicinal product provided regulation 11 control placing market regulation notified body mean relation task body designated notified respect task accordance european community (medical devices) regulation 1994 european community (active implantable medical devices) regulation 1994 european community (in vitro diagnostic medical devices) regulation 2001 meaning assigned by-- (a) article 2(42) medical device regulation (b) article 2(34) ivd medical device regulation applicable organ establishment authorisation mean authorisation granted pursuant regulation 6 european union (quality safety human organ intended transplantation) regulation 2012 (s.i no 325 2012) parallel import licence meaning assigned regulation 3(1) control placing market regulation project project authorisation meaning assigned regulation 3(1) protection animal regulation protection animal regulation mean european union (protection animal used scientific purposes) regulation 2012 (s.i no 543 2012) reduced dossier - complex refers application generic medicinal product accompanied reduced dossier containing additional data circumstance required directive 2001 83 ec reduced dossier - standard refers application generic medicinal product accompanied reduced dossier accordance directive 2001 83 ec service item mean application medicinal product designated authority qualifying reduced application fee basis product limited important us alternative authorised product exists subsequent extension application mean application additional pharmaceutical form strength medicinal product made subsequent first application relation product relation supplier authorisation meaning assigned regulation 3(1) protection animal regulation system procedure pack producer mean natural legal person referred in-- (a) article 22(1) (2) (3) medical device regulation 697 7 (b) article 12 council directive 93 42 eec 14th june 19934 applicable switching application mean application change classification medicinal product title vi directive 2001 83 ec traditional herbal medicinal product meaning assigned regulation 3(1) control placing market regulation type ia variation type ib variation type ii standard variation refer classification authority accordance commission regulation (ec) no 1234 2008 24 november 20085 user authorisation meaning assigned regulation 3(1) protection animal regulation wholesaler authorisation meaning assigned regulation 4(1) medicinal product (control wholesale distribution) regulation", "start_char": 703, "end_char": 13243, "source_path": "downloads\\2023\\2023_0697.pdf", "extraction_method": "pdfminer", "checksum": "sha256:2f26e4f67c6e8c1b721b56ab04ed177d6e8a27016037c5889b972b69326b3951", "cross_refs": []}
{"doc_id": "si-2023-0697-reg-2007", "parent_doc_id": "si-2023-0697", "section_id": "reg-2007", "section_label": "Regulation 2007.", "si_number": "S.I. No. 697 of 2023", "title": "2006)) of the Irish Medicines Board Act 1995 (No. 29 of 1995), hereby make", "year": 2023, "heading": null, "text_raw": "2007.", "text_norm": "2007", "start_char": 13243, "end_char": 13251, "source_path": "downloads\\2023\\2023_0697.pdf", "extraction_method": "pdfminer", "checksum": "sha256:2f26e4f67c6e8c1b721b56ab04ed177d6e8a27016037c5889b972b69326b3951", "cross_refs": []}
{"doc_id": "si-2023-0697-reg-3", "parent_doc_id": "si-2023-0697", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 697 of 2023", "title": "2006)) of the Irish Medicines Board Act 1995 (No. 29 of 1995), hereby make", "year": 2023, "heading": "3. Subject to Regulation 4, there shall be paid to the Authority in respect", "text_raw": "3. Subject to Regulation 4, there shall be paid to the Authority in respect \nof each and every matter set out in column 1 of the Schedule the corresponding \nfee set out in column 2 of the Schedule.", "text_norm": "3 subject regulation 4 shall paid authority respect every matter set column 1 schedule corresponding fee set column 2 schedule", "start_char": 13251, "end_char": 13451, "source_path": "downloads\\2023\\2023_0697.pdf", "extraction_method": "pdfminer", "checksum": "sha256:2f26e4f67c6e8c1b721b56ab04ed177d6e8a27016037c5889b972b69326b3951", "cross_refs": []}
{"doc_id": "si-2023-0697-reg-4", "parent_doc_id": "si-2023-0697", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 697 of 2023", "title": "2006)) of the Irish Medicines Board Act 1995 (No. 29 of 1995), hereby make", "year": 2023, "heading": "4. The Authority may, in circumstances where it considers it appropriate", "text_raw": "4. The Authority may, in circumstances where it considers it appropriate \nto do so, waive, remit or refund, either in whole or in part, any fee that would \notherwise be payable to it under Regulation 3.", "text_norm": "4 authority may circumstance considers appropriate waive remit refund either whole part fee would otherwise payable regulation 3", "start_char": 13451, "end_char": 13656, "source_path": "downloads\\2023\\2023_0697.pdf", "extraction_method": "pdfminer", "checksum": "sha256:2f26e4f67c6e8c1b721b56ab04ed177d6e8a27016037c5889b972b69326b3951", "cross_refs": []}
{"doc_id": "si-2023-0697-reg-5", "parent_doc_id": "si-2023-0697", "section_id": "reg-5", "section_label": "Regulation 5.", "si_number": "S.I. No. 697 of 2023", "title": "2006)) of the Irish Medicines Board Act 1995 (No. 29 of 1995), hereby make", "year": 2023, "heading": "5. The Health Products Regulatory Authority (Fees) Regulations 2022", "text_raw": "5. The Health Products Regulatory Authority (Fees) Regulations 2022 \n\n(S.I. No. 679 of 2022) are revoked. \n\n4 OJ No. L 169, 12.7.1993, p. 1. \n5 OJ No. L 334, 12.12.2008, p. 7. \n\n \n \n \n \n \n \n \n\f8 [697]", "text_norm": "5 health product regulatory authority (fees) regulation 2022 (s.i no 679 2022) revoked 4 oj no l 169 12.7.1993 p 1 5 oj no l 334 12.12.2008 p 7 8 697", "start_char": 13656, "end_char": 13859, "source_path": "downloads\\2023\\2023_0697.pdf", "extraction_method": "pdfminer", "checksum": "sha256:2f26e4f67c6e8c1b721b56ab04ed177d6e8a27016037c5889b972b69326b3951", "cross_refs": []}
{"doc_id": "si-2023-0697-schedule", "parent_doc_id": "si-2023-0697", "section_id": "schedule", "section_label": "SCHEDULE", "si_number": "S.I. No. 697 of 2023", "title": "2006)) of the Irish Medicines Board Act 1995 (No. 29 of 1995), hereby make", "year": 2023, "heading": "COLUMN 1 COLUMN 2", "text_raw": "SCHEDULE \n\nCOLUMN 1 COLUMN 2 \n\nFees for national applications for marketing authorisations € \n\nComplex dossier \n\nNational application \n\nEach additional form (same time) \n\nEach additional strength (same time) \n\nAdditional drug master file submitted \n\nReduced dossier – complex \n\nNational application \n\nEach additional form (same time) \n\nEach additional strength (same time) \n\nAdditional drug master file submitted \n\nReduced dossier – standard \n\nNational application \n\nEach additional form (same time) \n\nEach additional strength (same time) \n\nAdditional drug master file submitted \n\nSubsequent extension applications \n\nFirst additional form \n\nEach additional form (same time) \n\nFirst additional strength (existing form) \n\nEach additional strength (same time) \n\nAdditional drug master file submitted \n\n22,570 \n\n7,900 \n\n1,125 \n\n4,510 \n\n16,925 \n\n7,900 \n\n1,125 \n\n4,510 \n\n11,285 \n\n7,900 \n\n1,125 \n\n4,510 \n\n11,285 \n\n7,900 \n\n3,385 \n\n1,125 \n\n4,510 \n\n \n \n \n \n \n \n \n \n \n \n\f[697] 9 \n\nfor applications \n\nFees \nrecognition procedure and decentralised procedure \n\nfor marketing authorisations using mutual \n\nComplex dossier \n\nMutual recognition incoming \n\nEach additional form (same time) \n\nEach additional strength (same time) \n\nOutgoing mutual recognition supplement \n\nOutgoing mutual recognition supplement – mutual recognition \n\napplied for within twelve months of the national procedure ending \n\nDecentralised incoming \n\nDecentralised outgoing \n\nEach additional form (same time) \n\nEach additional strength (same time) \n\nAdditional supplement where there are 15 or more concerned \n\nMember States \n\nReduced dossier – complex \n\nMutual recognition incoming \n\nEach additional form (same time) \n\nEach additional strength (same time) \n\nOutgoing mutual recognition supplement \n\nOutgoing mutual recognition supplement – mutual recognition \n\napplied for within twelve months of the national procedure ending \n\nDecentralised incoming \n\nDecentralised outgoing \n\nEach additional form (same time) \n\nEach additional strength (same time) \n\n15,800 \n\n5,645 \n\n1,125 \n\n16,925 \n\n16,925 \n\n22,570 \n\n56,425 \n\n7,900 \n\n1,125 \n\n1,695 \n\n11,285 \n\n5,645 \n\n1,125 \n\n16,925 \n\n11,285 \n\n16,925 \n\n45,135 \n\n7,900 \n\n1,125 \n\n \n \n \n \n \n\f10 [697] \n\nAdditional supplement where there are 15 or more concerned \n\n1,695 \n\nMember States \n\nReduced dossier – standard \n\nMutual recognition incoming \n\nEach additional form (same time) \n\nEach additional strength (same time) \n\nOutgoing mutual recognition supplement \n\nOutgoing mutual recognition supplement – mutual recognition \n\napplied for within twelve months of the national procedure ending \n\nDecentralised incoming \n\nDecentralised outgoing \n\nEach additional form (same time) \n\nEach additional strength (same time) \n\n7,900 \n\n4,510 \n\n1,125 \n\n11,285 \n\n6,770 \n\n11,285 \n\n29,340 \n\n7,900 \n\n1,125 \n\nAdditional supplement where there are 15 or more concerned \n\n1,695 \n\nMember States \n\nSubsequent extension applications \n\nMutual recognition incoming (first additional form) \n\nMutual recognition incoming (first additional strength) \n\nMutual recognition incoming (subsequent additional strength) \n\n7,900 \n\n2,260 \n\n1,125 \n\nOutgoing mutual recognition/decentralised supplement (additional \n\n3,385 \n\nform) \n\nOutgoing mutual recognition/decentralised supplement (additional \n\n1,125 \n\nstrength) \n\nDecentralised incoming (first additional form) \n\nDecentralised outgoing (first additional form) \n\nEach additional form (same time) \n\nFirst additional strength (existing form) \n\n11,285 \n\n29,340 \n\n7,900 \n\n3,385 \n\n \n \n \n \n\fEach additional strength (same time) \n\nAdditional supplement where there are 15 or more concerned \n\nMember States \n\nSwitching applications \n\nSwitching applications \n\nApplication fee - per country at the same time or by \n\nvariation \n\nEach additional strength per country \n\nEach additional form per country \n\nParallel imports - dual pack registration \n\nDual pack registration of parallel imports - each additional \n\nstrength or form \n\n[697] 11 \n\n1,125 \n\n1,695 \n\n5,755 \n\n2,070 \n\n615 \n\n615 \n\n1,035 \n\n615 \n\nParallel imports where the originator is not on the Irish \n\n6,215 \n\nmarket \n\nChange of ownership per product range \n\n655 \n\nFees for variations to national marketing authorisations \n\nType IB variation \n\nType IB variation - reduced rate \n\nType II complex variation \n\nType II complex variation – reduced rate \n\nType II standard variation \n\nType II standard variation - reduced rate \n\nNotifications under Article 61(3) of Directive 2001/83/ EC \n\n580 \n\n295 \n\n3,235 \n\n630 \n\n630 \n\n315 \n\n310 \n\nNotifications under Article 61(3) of Directive 2001/83/EC - reduced \n\n155 \n\nrate \n\nMultiple variations capped fee (per product range) \n\n5,970 \n\n \n \n \n \n\f12 [697] \n\nMultiple variations capped fee (per product) \n\nWorksharing capped fee \n\n3,855 \n\n6,465 \n\nFees for variations to marketing authorisations under mutual recognition \nprocedure and decentralised procedure \n\nType IA variation outgoing mutual recognition / decentralised \n\nsupplement \n\nType IB variation outgoing mutual recognition / decentralised \n\nsupplement \n\nType IB variation - mutual recognition incoming \n\nType IB variation - mutual recognition incoming - reduced rate \n\n310 \n\n430 \n\n420 \n\n220 \n\nType II complex variation - outgoing mutual recognition / decentralised \n\n655 \n\nSupplement \n\nType II complex variation - mutual recognition incoming \n\n2,235 \n\nType II complex variation – mutual recognition incoming – reduced \n\n420 \n\nrate \n\nType II standard variation - mutual recognition incoming \n\nType II standard variation - mutual recognition incoming - reduced \n\nrate \n\nType II standard variation - outgoing mutual recognition / \n\ndecentralized supplement \n\nNotifications made under Article 61(3) of Directive 2001/83/EC \n\nNotifications made under Article 61(3) of Directive 2001/83/EC – \n\nreduced rate \n\n420 \n\n220 \n\n420 \n\n310 \n\n155 \n\nFees for the granting of a marketing authorisation on transfer to another \ncompany \n\nChange of ownership - related company – 1st marketing \n\n1,115 \n\nauthorisation within a range \n\n \n \n \n\f[697] 13 \n\nChange of ownership - related company – each additional marketing \n\n395 \n\nauthorisation within a range \n\nChange of ownership - non-related company – 1st marketing \n\n1,640 \n\nauthorisation within a range \n\nChange of ownership - non-related company – each additional \n\n395 \n\nmarketing authorisation within a range \n\nOther fees relating to the granting of marketing authorisations \n\nService item 755 \n\nNotification to become a listed organisation \n\nNotification Fee 10 \n\nFees for applications for wholesaler’s authorisations \n\nApplication fee \n\nVariation to authorisation - minor site technical \n\nVariation to authorisation – administrative \n\nVariation to authorisation – technical \n\nFees for applications for manufacturer’s authorisations \n\nApplication fee \n\nVariation to authorisation – administrative \n\nVariation to authorisation – technical \n\nVariation to authorisation – fast track \n\n690 \n\n495 \n\n270 \n\n745 \n\n2,300 \n\n345 \n\n960 \n\n1,355 \n\nFees for applications in relation to brokers register and active substances \nregister \n\nRegistration fee – importers and distributors of active substances and \nbrokers \n\nRegistration fee – manufacturers of active substances \n\nImmediate notification of a change which may impact on the quality \n\nor safety of the active substances \n\n310 \n\n550 \n\n960 \n\n \n \n \n \n \n \n \n\f14 [697] \n\nNotification of an administrative change to the active substances \n\n175 \n\nregister \n\nNotification of any change to the brokers register \n\n175 \n\nFees for applications for organ establishment authorisations \n\nApplication charge \n\nVariation to authorisation – administrative \n\nVariation to authorisation – technical \n\nAppeal to amend/revoke an authorisation \n\n2,300 \n\n345 \n\n960 \n\n620 \n\nScientific opinion on the non-viability of the cells/tissue, donation, \n\n3,320 \n\nprocurement testing \n\nFees for transferring of authorisation/registration to another company \n\nManufacturer’s authorisation and organ establishment authorisation \n\nRelated company \n\nUnrelated company \n\n1,375 \n\n2,300 \n\nWholesaler’s authorisation, registration on brokers register and \nregistration on active substances register \n\nRelated company \n\nUnrelated company \n\nCertificates of free sale – standard (4 certificates per request) \n\nCertificates of free sale – fast track (4 certificates per request) \n\nDuplicate certificates of free sale – each (available at time of initial \n\nrequest) \n\n450 \n\n690 \n\n185 \n\n345 \n\n25 \n\n \n \n \n \n \n \n \n \n \n \n\f[697] 15 \n\nNew national / decentralised registration standard charge - single \n\n840 \n\nstock \n\nNew national / decentralised registration standard charge - 2 or more \n\n1,265 \n\nstocks \n\nNew application - national rules scheme standard fee - single stock \n\n1,265 \n\nNew application - national rules scheme standard fee - 2 or more \n\n1,865 \n\nstocks \n\nMutual recognition incoming application standard fee - single stock \n\nMutual recognition incoming application standard fee - 2 or more \n\nstocks \n\nOutgoing mutual recognition / decentralised supplement \n\nNational variation – registration and national rules scheme \n\nNational variation – reduced rate – registrations and national rules \n\nscheme \n\nMutual recognition incoming variation \n\nMutual recognition incoming variation - reduced rate \n\nVariation – outgoing mutual recognition / decentralised supplement \n\nBulk variation for multiple changes to the Masterfile \n\n565 \n\n840 \n\n700 \n\n420 \n\n210 \n\n285 \n\n135 \n\n210 \n\n2,530 \n\nFees for applications in relation to traditional herbal medicinal products \n\nNational applications for certificates of traditional-use \n\nregistration \n\nNational application \n\nNational application where there is a monograph \n\nEach additional form (same time) \n\nEach additional strength (same time) \n\nAdditional drug master file submitted \n\n6,080 \n\n3,730 \n\n5,060 \n\n655 \n\n4,045 \n\n \n \n \n \n \n \n\f16 [697] \n\nExtension applications \n\nFirst additional form \n\nEach additional form (same time) \n\nFirst additional strength \n\nEach additional strength (same time) \n\nApplications for certificates of traditional-use registration under \nmutual recognition procedure and decentralised procedure \n\nMutual recognition incoming \n\nMutual recognition incoming - each additional form (same time) \n\nMutual recognition incoming - each additional strength (same time) \n\nOutgoing mutual recognition / decentralised supplement \n\nDecentralised outgoing/incoming \n\nEach additional form (same time) \n\nEach additional strength (same time) \n\nTraditional herbal medicinal products – national variations \n\nType IB variation – national \n\nType IB variation – reduced rate \n\nType II standard variation \n\nType II standard variation – reduced rate \n\nType II complex variation \n\nBulk variation for multiple changes \n\nTraditional herbal medicinal products – mutual recognition \nvariations \n\nType IB variation – mutual recognition incoming \n\nType IB variation – mutual recognition incoming - reduced rate \n\n6,080 \n\n5,060 \n\n2,745 \n\n655 \n\n4,250 \n\n2,840 \n\n655 \n\n5,525 \n\n6,080 \n\n5,060 \n\n655 \n\n465 \n\n240 \n\n495 \n\n250 \n\n2,610 \n\n5,220 \n\n335 \n\n175 \n\n \n \n \n \n \n \n\fType IB variation – outgoing mutual recognition supplement \n\nType II standard – mutual recognition incoming \n\nType II standard – mutual recognition incoming - reduced rate \n\nType II standard – outgoing mutual recognition supplement \n\nType II complex – mutual recognition incoming \n\nType II complex – outgoing mutual recognition supplement \n\nFees for export certificates and certification of documents \n\nStandard \n\nFast track \n\nAnnual maintenance fees \n\nMarketing authorisations and registrations \n\nFirst 10 marketing authorisations \n\nAdditional marketing authorisation \n\nDormant marketing authorisation \n\nParallel import licence \n\nParallel import licence - Dual pack \n\nCertificate of registration - homeopathic medicinal products \n\n[697] 17 \n\n345 \n\n335 \n\n175 \n\n335 \n\n1,785 \n\n520 \n\n185 \n\n345 \n\n805 \n\n1,005 \n\n463 \n\n135 \n\n65 \n\n65 \n\nCertificate of traditional-use registration - traditional herbal medicinal \n\n135 \n\nProducts \n\nManufacturer’s authorisations \n\nMajor site (more than 250 employees) \n\nLarge site (150-250 employees) \n\nMedium site (50-149 employees) \n\nSmall site (less than 50 employees) \n\n24,340 \n\n16,595 \n\n11,065 \n\n4,980 \n\n \n \n \n \n \n \n\f18 [697] \n\nHomeopathic manufacturing site \n\nWholesaler’s authorisations \n\nLarge full line \n\nMedium full line / short line \n\nSmall short line \n\nMinor site / Procure & supply \n\nActive substances register \n\nActive substances distributor \n\nActive substances importer \n\nActive substances manufacturer \n\nOrgan establishment authorisations \n\nMajor establishment (more than 250 employees) \n\nLarge establishment (150-250 employees) \n\nMedium establishment (50-149 employees) \n\nSmall establishment (less than 50 employees) \n\nMinor establishment (less than 5 employees) \n\nFees in relation to protection of animals used for scientific purposes \n\nProject authorisation fees \n\nProject application without ethical approval \n\nFast track project application \n\nBreeder/Supplier/User Authorisation fees \n\nBand 1: Small establishment with no animal facilities or \n\nestablishment with 1-3 individual authorisation holders \n\nBand 2: Establishment with 4-10 individual authorisation \n\n1,245 \n\n3,445 \n\n1,960 \n\n745 \n\n495 \n\n310 \n\n620 \n\n1,245 \n\n20,720 \n\n13,815 \n\n9,210 \n\n4,605 \n\n1,245 \n\n2,270 \n\n2,270 \n\n330 \n\n655 \n\n \n \n \n \n \n \n \n \n \n\fholders \n\nBand 3: Establishment with 11-20 individual authorisation \nholders \n\nBand 4: Establishment with 21-40 individual authorisation \nholders \n\nBand 5: Establishment with 41-70 individual authorisation \nholders \n\nBand 6: Establishment with \nauthorisation holders \n\n71-100 \n\nindividual \n\nBand 7: Establishment with 101-150 \nauthorisation holders \n\nindividual \n\nBand 8: Establishment with 151 – 200 individual \nauthorisation \n\nholders \n\n[697] 19 \n\n1,005 \n\n1,900 \n\n2,890 \n\n3,860 \n\n6,530 \n\n9,500 \n\nBand 9: Establishment with >200 individual authorisation \nholders \n\n12,470 \n\nIndividual authorisation fees \n\nApplication fee \n\nAnnual fee \n\nOnce-off authorisation - procedural training for a period \nof two months or less (reduced fee) \n\nFees for follow-up inspections \n\nPer day (per member of the inspection team) \n\nPart of day (per hour, per member of the inspection team) \n\n320 \n\n320 \n\n110 \n\n1,850 \n\n265 \n\nInspection/Audit fees (other than inspections in relation to the protection \nof animals used for scientific purposes) \n\nPer day (per member of the inspection team) \n\nPart of day (per hour, per member of the inspection team) \n\nInspection cancellation/rescheduling fee \n\n1,850 \n\n265 \n\n505 \n\n \n \n \n \n \n \n \n\f20 [697] \n\nEnforcement fees \n\nManufacturers \n\nMajor site (more than 250 employees) \n\nLarge site (150-250 employees) \n\nMedium site (50-149 employees) \n\nSmall site (less than 50 employees) \n\nWholesalers \n\nLarge full line \n\nMedium full line / short line \n\nMarketing authorisation / parallel import licence holders \n\n> 50 marketing authorisations / parallel import licences \n\n31-50 marketing authorisations / parallel import licences \n\n16-30 marketing authorisations / parallel import licences \n\n6-15 marketing authorisations / parallel import licences \n\n2,985 \n\n2,240 \n\n745 \n\n250 \n\n745 \n\n250 \n\n3,920 \n\n1,245 \n\n745 \n\n250 \n\n(Note: Companies classed as both manufacturer and wholesaler are charged the \nhigher of the two applicable charges. Marketing authorisation holders pay the \nto any manufacturer’s \nmarketing authorisation holder fee \nauthorisation / wholesaler’s authorisation fee.) \n\nin addition \n\nFees in relation to devices \n\nManufacturer or system and procedure pack producer or manufacturing \nfacility located in Ireland – annual fees \n\nManufacturer or system and procedure pack producer or \n\n31,060 \n\nmanufacturing facility - with more than 150 employees \n\nManufacturer or system and procedure pack producer or \n\n20,705 \n\nmanufacturing facility - with 100-150 employees \n\nManufacturer or system and procedure pack producer or \n\n15,530 \n\nmanufacturing facility - with 50-99 employees \n\n \n \n \n \n \n \n \n\fManufacturer or system and procedure pack producer or \n\nmanufacturing facility - with 16-49 employees \n\nManufacturer or system and procedure pack producer or \n\nmanufacturing facility - with 5-15 employees \n\n[697] 21 \n\n5,175 \n\n1,295 \n\nManufacturer or \nmanufacturing facility - with less than 5 employees or annual \n\nsystem and procedure pack producer or \n\n255 \n\nturnover of less than €500,000 \n\nAuthorised Representatives – annual fees \n\nType I Authorised Representative – representing a non-EU \n\n1,115 \n\nmanufacturer that manufactures low risk* devices (fee per \nmanufacturer) \n\nType II Authorised Representative – representing a non- EU \nmanufacturer that manufactures high risk** devices or a mix of \nhigh risk** & low risk* devices (fee per \n\nmanufacturer) \n\nCap on type I Authorised Representative \n\nCap on type II Authorised Representative \n\n1,520 \n\n5,575 \n\n7,600 \n\n(Note: * low risk devices means Class I general medical devices (as described \nin Council Directive 93/42/EEC of 14 June 19936 (‘MDD’) / the Medical \nDevices Regulation (‘MDR’)) and/or general category IVDs (as described in \nDirective 98/79/EC of the European Parliament and of the Council of 27 \nOctober 19982 (‘IVDD’)) / Class A (as described in the IVD Medical Devices \nRegulation (‘IVDR’).) \n\n(Note: ** high risk devices means Class IIa, IIb, III general medicinal devices \n(as described in MDD/MDR), active implantable medicinal devices, self-test \nIVD, Annex II IVD (as described in IVDD) or Class B, C and D (as described \nin IVDR).) \n\nDistributors and Importers – annual fees \n\nLarge distributor/importer (turnover greater than €15 million) \n\nMedium distributor/importer (turnover €3-€15 million) \n\nSmall distributor/importer (turnover under €3 million) \n\n4,660 \n\n2,590 \n\n1,295 \n\n \n \n \n \n\f22 [697] \n\nDistributor/importer turnover less than €500,000 \n\nAdditional supplement – Entities acting as both a distributor and \n\nimporter where turnover is more than €3 million \n\n255 \n\n1,015 \n\nNotified Body – annual fees 5,175 \n\nSummary evaluation review fees \n\nDevices using starting materials for which a TSE certificate of \n\n2,535 \n\nsuitability has been submitted \n\nDevices using starting materials for which a TSE certificate of \n\n5,075 \n\nsuitability has not been submitted \n\nEuropean Union Reference Laboratory (EURL) \n\nApplication \n\n2,740 \n\nVerification \n\nCertificate of free sale/letter confirming the location of the \n\n260 \n\nmanufacturing facility in Ireland (4 certificates per request) \n\nEach additional certificate of free sale/letter confirming the location of \n\n25 \n\nthe manufacturing facility in Ireland – (available at time of request) \n\nLetter confirming that a device or a list of devices are registered with the \n\n120 \n\nHPRA \n\nRegistration of Devices \n\nOnline Registration – Administration fee \n\n140 \n\nClinical Investigations and IVDR performance studies \n\nClass III and Class IIb medical devices, including relevant MDR \n\n4,365 \n\nAnnex XVI clinical investigations \n\nClass IIa and Class I devices, including relevant MDR Annex \n\n1,930 \n\nXVI clinical investigations \n\nNotifications and substantial modifications to notifications in \n\n205 \n\n \n \n \n \n \n \n \n\f[697] 23 \n\naccordance with MDR article 74(1), Article 82, IVDR Article 58(2) \nand IVDR Article 70(1) \n\nApplication for authorisation of in vitro diagnostic medical device \n(IVD) performance study under IVDR Article 58(1) (first \n\n2,535 \n\nsubmission) and PMPF study under IVDR Article 70(2) \n\nSubstantial modifications and technical amendment to a \n\n1,260 \n\npreviously approved clinical investigation/performance study \n\nResubmission of a clinical investigation/performance study \n\n1,930 \n\nfollowing a withdrawal or objection or if the application has lapsed \n\nResubmission of a clinical investigation/performance study - \n\n520 \n\nAcademic Sponsor \n\nDetermination of classification within the medical devices regulations \n\nDetermination not requiring a complex technical review (one \n\n285 \n\ndevice per request) \n\nComplex classification requests \n\nMDR Article 51 / IVDR Article 47 referral \n\nAppeal of a classification opinion \n\nDesignation Fee for a Notified Body \n\n1,035 \n\n10,000 \n\n610 \n\nInitial designation of a notified body and to the re-assessment of the \nnotified body under the new Device Regulations 745 and 746 of \n2017 \n\n10,355 \n\nExtensions to the scope (per extension) \n\n5,175 \n\nMedicinal Product / Medical Device - Drug Consultation Fees \n\nNew active substance \n\nEstablished active in new therapeutic area \n\nEstablished active and therapeutic area \n\n48,750 \n\n12,185 \n\n7,070 \n\n \n \n \n \n \n\f24 [697] \n\nVariations - Minor \n\nVariations - Major \n\n1,025 \n\n4,605 \n\nAssessments under Article 59 of the MDR and Article 54 of the IVDR \n\nAssessment fee \n\nMiscellaneous - Medical Devices \n\nSearch fee of medical devices data base \n\nDaily charge-out rate for Technical Services \n\nHourly charge-out rate for Technical Services \n\nHourly charge-out rate for Administrative Services \n\n4,060 \n\n65 \n\n1,700 \n\n270 \n\n80 \n\nFees in relation to clinical trials under European Communities (Clinical \nTrials on Medicinal Products for Human Use) Regulations 2004 (S.I. No. \n190 of 2004) \n\nAmendment to authorisation under Regulation 21 \n\nNotice of amendment \n\nNotice of amendment to include a new investigational medicinal \n\nproduct dossier \n\n410 \n\n880 \n\nFees in relation to clinical trials under European Union (Clinical Trials on \nMedicinal Products for Human Use) (Principal) Regulations 2022 (S.I. No. \n99 of 2022) \n\nApplications with an investigational medicinal product dossier \n\nMono National \n\nIreland – Reporting Member State \n\n3,420 \n\n8,700 \n\nIreland - Concerned Member State, initial, transitional or additional \n\n3,200 \n\napplications \n\nSupplement – Where Ireland subsequently becomes the Reporting \n\n5,280 \n\nMember State \n\nReporting Member State – 2nd & subsequent waves \n\n1,000 \n\n \n \n \n \n\f[697] 25 \n\nApplications with no investigational medicinal product dossier or \nwith a simplified investigational medicinal product dossier \n\nMono National \n\nIreland – Reporting Member State \n\n2,405 \n\n7,500 \n\nIreland - Concerned Member State, initial, transitional or additional \n\n2,135 \n\napplications \n\nSupplement – Where Ireland subsequently becomes the Reporting \n\n5,095 \n\nMember State \n\nReporting Member State – 2nd & subsequent waves \n\n1,000 \n\nSubstantial Modifications (Parts I & II or Part I only) – with \n\nthe addition of a new investigational medicinal product dossier \n\nMono National \n\nIreland – Reporting Member State \n\nIreland - Concerned Member State \n\nSubstantial Modifications – other \n\nMono National \n\nIreland – Reporting Member State \n\nIreland- Concerned Member State \n\nSubstantial Modifications – Part II only \n\nSubstantial Modification \n\n1,380 \n\n1,600 \n\n1,325 \n\n910 \n\n1,210 \n\n830 \n\n400 \n\n \n \n \n \n \n \n \n \n \n \n \n \n\f26 [697] \n\nFees for Appeals \n\nAppeal of clinical trial decision – Commercial \n\n1,890 \n\nFees for Safety Reports \n\nReview of Annual Safety reports/ Drug safety update reports \n\n220 \n\nFees for Inspections \n\nper day (per member of the inspection team) \n\nper hour (per member of the inspection team) \n\nFees for applications in relation to Exemptions under Article 61(5) of \nRegulation (EU) No. 536/2014 of the European Parliament and of the \nCouncil6 \n\nRegistration fee \n\nAmendment to registered details \n\n1,850 \n\n265 \n\n285 \n\n155 \n\nGIVEN under my Official Seal, \n\n21 December, 2023. \n\nSTEPHEN DONNELLY, \nMinister for Health. \n\n6 OJ No. L 158, 27.5.2014, p. 1. \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n\f[697] 27", "text_norm": "schedule column 1 column 2 fee national application marketing authorisation eur complex dossier national application additional form (same time) additional strength (same time) additional drug master file submitted reduced dossier - complex national application additional form (same time) additional strength (same time) additional drug master file submitted reduced dossier - standard national application additional form (same time) additional strength (same time) additional drug master file submitted subsequent extension application first additional form additional form (same time) first additional strength (existing form) additional strength (same time) additional drug master file submitted 22 570 7 900 1 125 4 510 16 925 7 900 1 125 4 510 11 285 7 900 1 125 4 510 11 285 7 900 3 385 1 125 4 510 697 9 application fee recognition procedure decentralised procedure marketing authorisation using mutual complex dossier mutual recognition incoming additional form (same time) additional strength (same time) outgoing mutual recognition supplement outgoing mutual recognition supplement - mutual recognition applied within twelve month national procedure ending decentralised incoming decentralised outgoing additional form (same time) additional strength (same time) additional supplement 15 concerned member state reduced dossier - complex mutual recognition incoming additional form (same time) additional strength (same time) outgoing mutual recognition supplement outgoing mutual recognition supplement - mutual recognition applied within twelve month national procedure ending decentralised incoming decentralised outgoing additional form (same time) additional strength (same time) 15 800 5 645 1 125 16 925 16 925 22 570 56 425 7 900 1 125 1 695 11 285 5 645 1 125 16 925 11 285 16 925 45 135 7 900 1 125 10 697 additional supplement 15 concerned 1 695 member state reduced dossier - standard mutual recognition incoming additional form (same time) additional strength (same time) outgoing mutual recognition supplement outgoing mutual recognition supplement - mutual recognition applied within twelve month national procedure ending decentralised incoming decentralised outgoing additional form (same time) additional strength (same time) 7 900 4 510 1 125 11 285 6 770 11 285 29 340 7 900 1 125 additional supplement 15 concerned 1 695 member state subsequent extension application mutual recognition incoming (first additional form) mutual recognition incoming (first additional strength) mutual recognition incoming (subsequent additional strength) 7 900 2 260 1 125 outgoing mutual recognition decentralised supplement (additional 3 385 form) outgoing mutual recognition decentralised supplement (additional 1 125 strength) decentralised incoming (first additional form) decentralised outgoing (first additional form) additional form (same time) first additional strength (existing form) 11 285 29 340 7 900 3 385 additional strength (same time) additional supplement 15 concerned member state switching application switching application application fee - per country time variation additional strength per country additional form per country parallel import - dual pack registration dual pack registration parallel import - additional strength form 697 11 1 125 1 695 5 755 2 070 615 615 1 035 615 parallel import originator irish 6 215 market change ownership per product range 655 fee variation national marketing authorisation type ib variation type ib variation - reduced rate type ii complex variation type ii complex variation - reduced rate type ii standard variation type ii standard variation - reduced rate notification article 61(3) directive 2001 83 ec 580 295 3 235 630 630 315 310 notification article 61(3) directive 2001 83 ec - reduced 155 rate multiple variation capped fee (per product range) 5 970 12 697 multiple variation capped fee (per product) worksharing capped fee 3 855 6 465 fee variation marketing authorisation mutual recognition procedure decentralised procedure type ia variation outgoing mutual recognition decentralised supplement type ib variation outgoing mutual recognition decentralised supplement type ib variation - mutual recognition incoming type ib variation - mutual recognition incoming - reduced rate 310 430 420 220 type ii complex variation - outgoing mutual recognition decentralised 655 supplement type ii complex variation - mutual recognition incoming 2 235 type ii complex variation - mutual recognition incoming - reduced 420 rate type ii standard variation - mutual recognition incoming type ii standard variation - mutual recognition incoming - reduced rate type ii standard variation - outgoing mutual recognition decentralized supplement notification made article 61(3) directive 2001 83 ec notification made article 61(3) directive 2001 83 ec - reduced rate 420 220 420 310 155 fee granting marketing authorisation transfer another company change ownership - related company - 1st marketing 1 115 authorisation within range 697 13 change ownership - related company - additional marketing 395 authorisation within range change ownership - non-related company - 1st marketing 1 640 authorisation within range change ownership - non-related company - additional 395 marketing authorisation within range fee relating granting marketing authorisation service item 755 notification become listed organisation notification fee 10 fee application wholesaler authorisation application fee variation authorisation - minor site technical variation authorisation - administrative variation authorisation - technical fee application manufacturer authorisation application fee variation authorisation - administrative variation authorisation - technical variation authorisation - fast track 690 495 270 745 2 300 345 960 1 355 fee application relation broker register active substance register registration fee - importer distributor active substance broker registration fee - manufacturer active substance immediate notification change may impact quality safety active substance 310 550 960 14 697 notification administrative change active substance 175 register notification change broker register 175 fee application organ establishment authorisation application charge variation authorisation - administrative variation authorisation - technical appeal amend revoke authorisation 2 300 345 960 620 scientific opinion non-viability cell tissue donation 3 320 procurement testing fee transferring authorisation registration another company manufacturer authorisation organ establishment authorisation related company unrelated company 1 375 2 300 wholesaler authorisation registration broker register registration active substance register related company unrelated company certificate free sale - standard (4 certificate per request) certificate free sale - fast track (4 certificate per request) duplicate certificate free sale - (available time initial request) 450 690 185 345 25 697 15 new national decentralised registration standard charge - single 840 stock new national decentralised registration standard charge - 2 1 265 stock new application - national rule scheme standard fee - single stock 1 265 new application - national rule scheme standard fee - 2 1 865 stock mutual recognition incoming application standard fee - single stock mutual recognition incoming application standard fee - 2 stock outgoing mutual recognition decentralised supplement national variation - registration national rule scheme national variation - reduced rate - registration national rule scheme mutual recognition incoming variation mutual recognition incoming variation - reduced rate variation - outgoing mutual recognition decentralised supplement bulk variation multiple change masterfile 565 840 700 420 210 285 135 210 2 530 fee application relation traditional herbal medicinal product national application certificate traditional-use registration national application national application monograph additional form (same time) additional strength (same time) additional drug master file submitted 6 080 3 730 5 060 655 4 045 16 697 extension application first additional form additional form (same time) first additional strength additional strength (same time) application certificate traditional-use registration mutual recognition procedure decentralised procedure mutual recognition incoming mutual recognition incoming - additional form (same time) mutual recognition incoming - additional strength (same time) outgoing mutual recognition decentralised supplement decentralised outgoing incoming additional form (same time) additional strength (same time) traditional herbal medicinal product - national variation type ib variation - national type ib variation - reduced rate type ii standard variation type ii standard variation - reduced rate type ii complex variation bulk variation multiple change traditional herbal medicinal product - mutual recognition variation type ib variation - mutual recognition incoming type ib variation - mutual recognition incoming - reduced rate 6 080 5 060 2 745 655 4 250 2 840 655 5 525 6 080 5 060 655 465 240 495 250 2 610 5 220 335 175 type ib variation - outgoing mutual recognition supplement type ii standard - mutual recognition incoming type ii standard - mutual recognition incoming - reduced rate type ii standard - outgoing mutual recognition supplement type ii complex - mutual recognition incoming type ii complex - outgoing mutual recognition supplement fee export certificate certification document standard fast track annual maintenance fee marketing authorisation registration first 10 marketing authorisation additional marketing authorisation dormant marketing authorisation parallel import licence parallel import licence - dual pack certificate registration - homeopathic medicinal product 697 17 345 335 175 335 1 785 520 185 345 805 1 005 463 135 65 65 certificate traditional-use registration - traditional herbal medicinal 135 product manufacturer authorisation major site (more 250 employees) large site (150-250 employees) medium site (50-149 employees) small site (less 50 employees) 24 340 16 595 11 065 4 980 18 697 homeopathic manufacturing site wholesaler authorisation large full line medium full line short line small short line minor site procure supply active substance register active substance distributor active substance importer active substance manufacturer organ establishment authorisation major establishment (more 250 employees) large establishment (150-250 employees) medium establishment (50-149 employees) small establishment (less 50 employees) minor establishment (less 5 employees) fee relation protection animal used scientific purpose project authorisation fee project application without ethical approval fast track project application breeder supplier user authorisation fee band 1 small establishment animal facility establishment 1-3 individual authorisation holder band 2 establishment 4-10 individual authorisation 1 245 3 445 1 960 745 495 310 620 1 245 20 720 13 815 9 210 4 605 1 245 2 270 2 270 330 655 holder band 3 establishment 11-20 individual authorisation holder band 4 establishment 21-40 individual authorisation holder band 5 establishment 41-70 individual authorisation holder band 6 establishment authorisation holder 71-100 individual band 7 establishment 101-150 authorisation holder individual band 8 establishment 151 - 200 individual authorisation holder 697 19 1 005 1 900 2 890 3 860 6 530 9 500 band 9 establishment 200 individual authorisation holder 12 470 individual authorisation fee application fee annual fee once-off authorisation - procedural training period two month le (reduced fee) fee follow-up inspection per day (per member inspection team) part day (per hour per member inspection team) 320 320 110 1 850 265 inspection audit fee (other inspection relation protection animal used scientific purposes) per day (per member inspection team) part day (per hour per member inspection team) inspection cancellation rescheduling fee 1 850 265 505 20 697 enforcement fee manufacturer major site (more 250 employees) large site (150-250 employees) medium site (50-149 employees) small site (less 50 employees) wholesaler large full line medium full line short line marketing authorisation parallel import licence holder 50 marketing authorisation parallel import licence 31-50 marketing authorisation parallel import licence 16-30 marketing authorisation parallel import licence 6-15 marketing authorisation parallel import licence 2 985 2 240 745 250 745 250 3 920 1 245 745 250 (note company classed manufacturer wholesaler charged higher two applicable charge marketing authorisation holder pay manufacturer marketing authorisation holder fee authorisation wholesaler authorisation fee.) addition fee relation device manufacturer system procedure pack producer manufacturing facility located ireland - annual fee manufacturer system procedure pack producer 31 060 manufacturing facility - 150 employee manufacturer system procedure pack producer 20 705 manufacturing facility - 100-150 employee manufacturer system procedure pack producer 15 530 manufacturing facility - 50-99 employee manufacturer system procedure pack producer manufacturing facility - 16-49 employee manufacturer system procedure pack producer manufacturing facility - 5-15 employee 697 21 5 175 1 295 manufacturer manufacturing facility - le 5 employee annual system procedure pack producer 255 turnover le eur500 000 authorised representative - annual fee type authorised representative - representing non-eu 1 115 manufacturer manufacture low risk device (fee per manufacturer) type ii authorised representative - representing non- eu manufacturer manufacture high risk device mix high risk low risk device (fee per manufacturer) cap type authorised representative cap type ii authorised representative 1 520 5 575 7 600 (note low risk device mean class general medical device (as described council directive 93 42 eec 14 june 19936 ( mdd ) medical device regulation ( mdr )) general category ivds (as described directive 98 79 ec european parliament council 27 october 19982 ( ivdd )) class (as described ivd medical device regulation ( ivdr ).) (note high risk device mean class iia iib iii general medicinal device (as described mdd mdr) active implantable medicinal device self-test ivd annex ii ivd (as described ivdd) class b c (as described ivdr).) distributor importer - annual fee large distributor importer (turnover greater eur15 million) medium distributor importer (turnover eur3-eur15 million) small distributor importer (turnover eur3 million) 4 660 2 590 1 295 22 697 distributor importer turnover le eur500 000 additional supplement - entity acting distributor importer turnover eur3 million 255 1 015 notified body - annual fee 5 175 summary evaluation review fee device using starting material tse certificate 2 535 suitability submitted device using starting material tse certificate 5 075 suitability submitted european union reference laboratory (eurl) application 2 740 verification certificate free sale letter confirming location 260 manufacturing facility ireland (4 certificate per request) additional certificate free sale letter confirming location 25 manufacturing facility ireland - (available time request) letter confirming device list device registered 120 hpra registration device online registration - administration fee 140 clinical investigation ivdr performance study class iii class iib medical device including relevant mdr 4 365 annex xvi clinical investigation class iia class device including relevant mdr annex 1 930 xvi clinical investigation notification substantial modification notification 205 697 23 accordance mdr article 74(1) article 82 ivdr article 58(2) ivdr article 70(1) application authorisation vitro diagnostic medical device (ivd) performance study ivdr article 58(1) (first 2 535 submission) pmpf study ivdr article 70(2) substantial modification technical amendment 1 260 previously approved clinical investigation performance study resubmission clinical investigation performance study 1 930 following withdrawal objection application lapsed resubmission clinical investigation performance study - 520 academic sponsor determination classification within medical device regulation determination requiring complex technical review (one 285 device per request) complex classification request mdr article 51 ivdr article 47 referral appeal classification opinion designation fee notified body 1 035 10 000 610 initial designation notified body re-assessment notified body new device regulation 745 746 2017 10 355 extension scope (per extension) 5 175 medicinal product medical device - drug consultation fee new active substance established active new therapeutic area established active therapeutic area 48 750 12 185 7 070 24 697 variation - minor variation - major 1 025 4 605 assessment article 59 mdr article 54 ivdr assessment fee miscellaneous - medical device search fee medical device data base daily charge-out rate technical service hourly charge-out rate technical service hourly charge-out rate administrative service 4 060 65 1 700 270 80 fee relation clinical trial european community (clinical trial medicinal product human use) regulation 2004 (s.i no 190 2004) amendment authorisation regulation 21 notice amendment notice amendment include new investigational medicinal product dossier 410 880 fee relation clinical trial european union (clinical trial medicinal product human use) (principal) regulation 2022 (s.i no 99 2022) application investigational medicinal product dossier mono national ireland - reporting member state 3 420 8 700 ireland - concerned member state initial transitional additional 3 200 application supplement - ireland subsequently becomes reporting 5 280 member state reporting member state - 2nd subsequent wave 1 000 697 25 application investigational medicinal product dossier simplified investigational medicinal product dossier mono national ireland - reporting member state 2 405 7 500 ireland - concerned member state initial transitional additional 2 135 application supplement - ireland subsequently becomes reporting 5 095 member state reporting member state - 2nd subsequent wave 1 000 substantial modification (parts ii part only) - addition new investigational medicinal product dossier mono national ireland - reporting member state ireland - concerned member state substantial modification - mono national ireland - reporting member state ireland- concerned member state substantial modification - part ii substantial modification 1 380 1 600 1 325 910 1 210 830 400 26 697 fee appeal appeal clinical trial decision - commercial 1 890 fee safety report review annual safety report drug safety update report 220 fee inspection per day (per member inspection team) per hour (per member inspection team) fee application relation exemption article 61(5) regulation (eu) no 536 2014 european parliament council6 registration fee amendment registered detail 1 850 265 285 155 given official seal 21 december 2023 stephen donnelly minister health 6 oj no l 158 27.5.2014 p 1 697 27", "start_char": 13859, "end_char": 37150, "source_path": "downloads\\2023\\2023_0697.pdf", "extraction_method": "pdfminer", "checksum": "sha256:2f26e4f67c6e8c1b721b56ab04ed177d6e8a27016037c5889b972b69326b3951", "cross_refs": []}
{"doc_id": "si-2023-0697-explanatory-note", "parent_doc_id": "si-2023-0697", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 697 of 2023", "title": "2006)) of the Irish Medicines Board Act 1995 (No. 29 of 1995), hereby make", "year": 2023, "heading": "(This note is not part of the instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the instrument and does not purport to be a legal \ninstrument.) \n\nThe purpose of these Regulations is to provide for the revision of fees payable \nto the Health Products Regulatory Authority (formerly the Irish Medicines \nBoard) pursuant to Section 13 of the Irish Medicines Board Act 1995. \n\nThese Regulations revoke the Health Products Regulatory Authority (Fees) \nRegulations 2022 (S.I. No. 679 of 2022). \n\nThese Regulations may be cited as the Health Products Regulatory Authority \n(Fees) Regulations 2023. \n\n \n \n \n \n \n \n \n\f28 [697] \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \nBÓTHAR BHAILE UÍ BHEOLÁIN, \nCILL MHAIGHNEANN, \nBAILE ÁTHA CLIATH 8, \nD08 XAO6 \n\nTeil: 046 942 3100 \nr-phost: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \nMOUNTSHANNON ROAD, \nKILMAINHAM, DUBLIN 8, \nD08 XAO6 \n\nTel: 046 942 3100 \nE-mail: publications@opw.ie \n—————— \n\n€ 6.50 \n\n(DH-514) 75. 12/23. Propylon.", "text_norm": "explanatory note (this note part instrument purport legal instrument.) purpose regulation provide revision fee payable health product regulatory authority (formerly irish medicine board) pursuant section 13 irish medicine board act 1995 regulation revoke health product regulatory authority (fees) regulation 2022 (s.i no 679 2022) regulation may cited health product regulatory authority (fees) regulation 2023 28 697 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais bothar bhaile ui bheolain cill mhaighneann baile atha cliath 8 d08 xao6 teil 046 942 3100 r-phost publication opw.ie ------------ dublin published stationery office purchased government publication mountshannon road kilmainham dublin 8 d08 xao6 tel 046 942 3100 e-mail publication opw.ie ------------ eur 6.50 (dh-514) 75 12 23 propylon", "start_char": 37150, "end_char": 38218, "source_path": "downloads\\2023\\2023_0697.pdf", "extraction_method": "pdfminer", "checksum": "sha256:2f26e4f67c6e8c1b721b56ab04ed177d6e8a27016037c5889b972b69326b3951", "cross_refs": []}
